WHO ICTRP trial
Comparison of the effect of letrozole and misoprostol and misoprostol alone on…
IRCT20250505065609N1 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT20250505065609N1 |
|---|---|
| Public title | Comparison of the effect of letrozole and misoprostol and misoprostol alone on pregnancy remnants |
| Scientific title | Comparison of the effect of letrozole and misoprostol and misoprostol alone on pregnancy remnants |
| Primary sponsor | Sanandaj University of Medical Sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Phase | 2-3 |
| Countries | Iran (Islamic Republic of) |
| Conditions | Legal abortion. Termination of pregnancy, affecting fetus and newborn;P96.4 |
| Interventions | Intervention 1: In the intervention group, patients receive a single oral dose of 20 mg Letrozole, produced by Abureyhan Pharmaceutical Company. Additionally, misoprostol is administered as an adjunct medication according to the FIGO… |
| Registration date | Sep 12, 2025 |
| Target size | 100 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: